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Abstract
Vitamin D deficiency is common in pregnant women and may contribute to adverse 
events in pregnancy such as preeclampsia (PET). To date, studies of vitamin D and 
PET have focused primarily on serum concentrations vitamin D, 25-hydroxyvitamin 
D3 (25(OH)D3) later in pregnancy. The aim here was to determine whether a more 
comprehensive analysis of vitamin D metabolites earlier in pregnancy could provide 
predictors of PET. Using samples from the SCOPE pregnancy cohort, multiple vitamin D 
metabolites were quantified by liquid chromatography–tandem mass spectrometry in 
paired serum and urine prior to the onset of PET symptoms. Samples from 50 women 
at pregnancy week 15 were analysed, with 25 (50%) developing PET by the end of the 
pregnancy and 25 continuing with uncomplicated pregnancy. Paired serum and urine 
from non-pregnant women (n = 9) of reproductive age were also used as a control. 
Serum concentrations of 25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 24,25(OH)2D3 and  
3-epi-25(OH)D3 were measured and showed no significant difference between women 
with uncomplicated pregnancies and those developing PET. As previously reported, 
serum 1,25(OH)2D3 was higher in all pregnant women (in the second trimester), but 
serum 25(OH)D2 was also higher compared to non-pregnant women. In urine, 25(OH)D3 
and 24,25(OH)2D3 were quantifiable, with both metabolites demonstrating significantly 
lower (P < 0.05) concentrations of both of these metabolites in those destined to develop 
PET. These data indicate that analysis of urinary metabolites provides an additional 
insight into vitamin D and the kidney, with lower urinary 25(OH)D3 and 24,25(OH)2D3 
excretion being an early indicator of a predisposition towards developing PET.
Introduction
Pre-eclampsia (PET) is a pregnancy-specific, multisystem 
syndrome with endothelial dysfunction and presenting 
with hypertension and pathologic renal protein 
excretion. Complicating up to 8% of pregnancies (1, 2, 3), 
PET is associated with significant maternal and perinatal 
mortality and morbidity (4, 5). Despite recognition of PET 
risk factors, such as raised body mass index, ethnicity, 
advanced maternal age, pre-existing hypertension and/or 
chronic renal disease, PET often complicates otherwise 
uncomplicated nulliparous pregnancies with severe 
maternal–fetal consequences (5, 6).
The key predisposing event in PET is uteroplacental 
maldevelopment with abnormal decidual maternal 
spiral artery remodelling by invading fetal extravillous 
trophoblast cells in the late first and second trimester. 
This often precedes the onset of clinical disease, which 
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later ensues secondary to tissue hypoxia, oxidative stress 
and release of anti-angiogenic and pro-inflammatory 
factors into the maternal circulation, which result 
in generalised systemic endothelial dysfunction (7). 
Consequently, there has been considerable research 
interest in the identification of ‘early biomarkers’ of PET, 
including anti-angiogenic factors, hormones, adhesion 
molecules, placental perfusion measures and vasodilators 
such as placental soluble fms-like tyrosine kinase (sFlt-1), 
soluble endoglin (sEng), maternal spiral artery resistance, 
pulsatility index and placental growth factor (PlGF) (8, 9, 
10, 11). To date, systematic analysis of the efficacy of these 
biomarkers has been relatively inconsistent with high 
intra-study heterogeneity (10, 12).
The kidney is a key organ affected by PET. In response 
to normal pregnancy, significant renal adaptations 
ensue, including marked glomerular hyperfiltration 
and increased effective renal plasma flow. In PET, these 
functional changes differ with a significantly lower 
glomerular filtration rate and progressive glomerular 
injury (13, 14, 15), as evidenced by the development of 
significant proteinuria. Potential pre-clinical markers 
of renal injury, including urinary podocytes, podocyte-
specific proteinuria nephrin and urinary albumin are 
now also being sought (16, 17). The kidneys are also 
the major site for vitamin D metabolism, expressing the 
25-hydroxyvitamin D3 1α-hydroxylase (1α-hydroxylase) 
enzyme that synthesises 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) from precursor 25-hydroxyvitamin 
D3 (25(OH)D3), as well as 25-hydroxyvitamin D-24-
hydroxylase (24-hydroxylase) and the vitamin D receptor 
(VDR) (18, 19). In uncomplicated pregnancy, significant 
changes in vitamin D physiology arise, with a surge in 
maternal serum 1,25(OH)2D3 from the first trimester (20). 
During pregnancy 1,25(OH)2D3 is also synthesised by the 
human placenta and decidua via localised expression of 
1α-hydroxylase, which is greatest in the first and second 
trimester. Coincident expression of placental VDR, 
24-hydroxylase, vitamin D-binding protein and vitamin 
D-25-hydroxylase, suggest an autocrine/paracrine role 
for 1,25(OH)2D3 in the placenta (21, 22, 23, 24, 25). The 
role of vitamin D inactivation and renal clearance in 
pregnancy are to be defined.
Vitamin D deficiency, defined as a serum 25(OH)D3 
<50 nM, is highly prevalent in pregnant women (26, 27), 
and recent studies have reported association between 
maternal serum 25(OH)D3 levels and PET (28, 29, 30, 31, 
32). A recent systematic review and meta-analysis, which 
included 11 observational studies, found a significant 
inverse relationship between maternal 25(OH)D3 and PET 
risk in 5 of these studies. Meta-analyses similarly suggested 
an inverse relationship between maternal 25(OH)D3 
and PET risk, but could not prove causality (33,  34). 
This heterogeneity reflects our limited understanding 
of the effects of vitamin D during pregnancy at the 
cellular level and suggests that measurement of serum 
25(OH)D3 alone may be too simplistic. Other vitamin 
D metabolites such as 1,25(OH)2D3 (35), 3-epi-25(OH)
D3 (36) and 24-hydroxylated vitamin D metabolites 
(24,25(OH)2D3) have received recent attention, reflecting 
in part the significant developments in high-sensitivity 
analytical methods for quantification of these metabolites 
(21, 37). Preliminary studies by our group have shown 
that pregnant women with PET demonstrate aberrant 
vitamin D metabolism in the 3rd trimester (21). What 
remains unclear is whether dysregulation precedes PET, 
or is a consequence of the onset of this disorder. The 
principal objective of this study was to determine whether 
comprehensive analysis of vitamin D metabolites earlier 
in pregnancy could be utilised to predict PET. Clarification 
of this has major functional, prognostic and therapeutic 
implications for the management of PET.
Materials and methods
Ethical approval
Matched serum and urine samples were purchased from the 
SCOPE (Screening for Pregnancy Endpoints) Ireland study 
(Clinical Research Ethics Committee (REC) of the Cork 
Teaching Hospital: ECM5 (10) (05.02.08 approval)). The 
SCOPE study was conducted according to the Declaration 
of Helsinki guidelines. Appropriate Health Research 
Authority – West Midlands, Edgbaston REC (14/WM/1146 
RG_14-194 (09.12.2016 approval)) and material transfer 
agreement (MTA) (15.04.2016 15-1386) approvals were 
acquired by the University of Birmingham (UoB) prior to 
shipment (June 2016). A non-pregnant female cohort was 
recruited at UoB (Birmingham, UK) (REC 14/WM/1146 
RG_14-194 (09.12.2016 approval)). Written informed 
consent was obtained from all participants recruited.
Sample collection
Overall, 1768 participants who attended for antenatal 
care at Cork University Maternity Hospital, Cork, 
Ireland (528N) were recruited to SCOPE (Screening for 
Pregnancy Endpoints) Ireland study (www.anzctr.org.au; 
ACTRN12607000551493) early in the 2nd trimester 
(March 2008–January 2011). These were collected as part 
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of a large international pregnancy cohort study with the 
primary aim of developing screening tests for PET, small-
for gestational age (SGA) and spontaneous preterm birth. 
Six research centres participated in Auckland, Adelaide, 
London, Leeds, Manchester and Cork. The main inclusion 
criteria were a low-risk pregnancy, a singleton pregnancy 
<15  weeks of gestation and no previous pregnancy 
>20-week gestation. Specific exclusion criteria were 
applied: a predetermined high risk of PET, an SGA baby or 
spontaneous preterm birth due to an underlying medical 
condition (including chronic hypertension requiring 
antihypertensive drugs, diabetes, renal disease, systemic 
lupus erythematosus, antiphospholipid syndrome, 
sickle cell disease, HIV, previous cervical knife cone 
biopsy, ≥3 terminations of pregnancy, ≥3 miscarriages 
or current ruptured membranes), known major fetal 
anomaly or abnormal karyotype or an intervention that 
could modify pregnancy outcome (such as aspirin use 
or cervical cerclage) (38). The estimated date of delivery 
was calculated from a certain last menstrual period (LMP) 
date. Of the 1768 participants, 68 (3.8%) developed PET.
For the current study, paired serum (750 µL) and urine 
(900 µL) was obtained at 15-week gestation from a subset 
of 50 women recruited to the SCOPE study. Of these, 25 
prospectively developed PET, and 25 were normotensive 
uncomplicated pregnancies, matched for maternal 
age, ethnicity and body mass index (BMI). Further 
detailed demographic details were obtained, including 
supplement and dietary intake of vitamin D, participant 
co-morbidities, disease course and maternofetal outcome. 
PET was defined as a systolic blood pressure (BP) 
≥140 mmHg or diastolic ≥90 mmHg on ≥2 occasions 4 h 
apart after 20-week gestation. Onset was either before the 
onset of labour or postpartum, with either proteinuria 
(24-h urinary protein ≥300 mg or a spot urine protein: 
creatinine ratio ≥30 mg/mmol creatinine or urine dipstick 
protein ≥2) or any multisystem complication of PET also 
present (38). Samples were anonymised by the Cork SCOPE 
study group, with University of Birmingham researchers 
blinded to the clinical outcome until after completion of 
the serum/urine vitamin D metabolite analysis. A healthy 
non-pregnant female ‘control’ group (NP; n = 9) was also 
recruited at the University of Birmingham to provide 
whole blood and urine for comparative vitamin D 
metabolite analysis.
Serum vitamin D metabolite quantification
Using LC MS–MS technology, comprehensive analysis 
of serum vitamin D metabolites (25OHD3, 25OHD2, 
3-epi-25OHD3, 1α,25(OH)2D3 and 24,25(OH)2D3) was 
performed using previously reported methods (21, 39). 
In brief, samples were prepared for analysis by protein 
precipitation and supported liquid–liquid extraction 
(SLE). Analysis of serum was performed on a Waters 
ACQUITY ultra-performance liquid chromatography 
(UPLC) coupled to a Waters Xevo TQ-S mass spectrometer. 
Analysis was carried out in multiple reaction monitoring 
(MRM) mode, the optimised MRM transitions are 
described previously (32). The LC–MS/MS method 
has been validated previously based on US Food and 
Drug Administration guidelines for analysis of these 
metabolites (32).
Urinary vitamin D metabolite quantification
Maternal urine samples were obtained at recruitment 
and stored at −80°C until use. Quantitative analysis 
of urinary de-conjugated vitamin D metabolites in 
spot urine samples was performed using a novel liquid 
chromatography tandem-mass spectrometry (LC–MS/MS) 
methodology. This was optimised from a method 
developed by Ogawa and coworkers, which quantified 
25(OH)D3 and 24,25(OH)2D3 in spot urine samples 
obtained from healthy male participants using liquid 
chromatography/electrospray ionization-tandem 
mass spectrometry (LC/ESI-MS/MS) combined with 
derivatization using an ESI-enhancing reagent, 
4-(4′-dimethylaminophenyl)-1,2,4-triazoline-3,5-dione 
(DAPTAD) (40).
Spot urine (700 µL) samples were de-conjugated 
with β-glucuronidase 1000 units and extracted by solid 
phase extraction as previously described (40), hydrolysis 
was carried out at 55°C. A Waters Xevo-MS coupled 
to an AQUITY UPLC was used for analysis following 
derivatisation with 4-phenyl-1,2,4-triazoline-3,5-
dione (PTAD) to enable the required limit of detection 
for analysis of these less abundant samples in urine. 
A  Waters C18 column (2.1 × 50 mm 1.7 µm) was used 
for separation of metabolites. The mass spectrometry 
conditions were desolvation temperature 500°C, 
capillary voltage 2.20 kV and source temperature 150°C. 
The mobile phase was methanol/water/0.1% formic 
acid. The initial mobile phase was 50% increasing to 
98% methanol over 2.75 min and held until 3 min. 
The mobile phase was returned to 50% at 3.7 min and 
held until the end of the sample run at 5 min. The flow 
rate was 0.5 mL/min, and sample injection volume was 
20 µL. Optimised multiple reaction monitoring (MRM) 
transitions were obtained by full and daughter scan 
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runs of each compound. MRM transitions are listed in 
Supplementary Table  1 (see section on supplementary 
data given at the end of this article).
Urinary creatinine correction
Urinary creatinine correction was performed for all urine 
vitamin D metabolite measurements to account for inter-
subject variations in urinary dilution and creatinine 
clearance. Creatinine was measured in 10 µL urine by an 
automated Jaffe reaction assay (R&D Systems, KJG005). 
This utilises a colorimetric Jaffe reaction between 
creatinine and picrate acid to permit accurate and rapid 
quantification (41). The reaction optical density was 
measured using a microplate reader at a wavelength of 
490 nm. Urinary levels of vitamin D metabolites were 
then normalised to the sample creatinine content (ng/g 
of creatinine).
Statistics
Unless otherwise stated, data are shown as median values 
with interquartile ranges (IQR). All statistical analyses were 
carried out using GraphPad Prism, V7 Software Inc. Data 
were compared using either Mann–Whitney or Kruskal–
Wallis (non-parametric) tests based upon ranks (P < 0.05). 
Spearman’s (non-parametric) correlation co-efficient 
was utilised to calculate R value and 95% confidence 
intervals (P < 0.05).
Results
Sample description
Overall, in the Ireland SCOPE data set, the incidence 
of PET was 3.8% (68/1768 pregnancies). Comparative 
analysis of 25 women from the 68 PET pregnancies and 25 
from the 1768 healthy control pregnancies is presented 
in Table  1, with both maternal and fetal demographics 
reported. To minimise the potential seasonal effects 
upon vitamin D status, pregnant women were recruited 
across the calendar year, 21 in summer (June through 
October) and 29 in winter (November through May). 
Median gestational age (GA) at recruitment was 16 weeks 
(15.0–16  week) and 15  weeks (15.0–16.0  week) for the 
pregnant normotensive and PET groups, respectively. The 
time of urine specimen collection was not uniform, with 
median 10:00 h (range 9.00–14.00) and 12:00 h (range 
9.00–15.00) collection in normotensive and PET pregnant 
groups, respectively. Concerning dietary intake of vitamin 
D, 15 (10 normotensive and 5 PET women) reported 
intake of the recommended daily dose of vitamin D 
(400 IU/day) pre-pregnancy. In the first trimester 
(≤12 week), 12 participants (9 normotensive and 3 PET) 
took 400 IU vitamin D daily, of which 9 (7 normotensive 
and 2 PET) had continued from pre-conception.
As summarised in Table  1, of the 25 women who 
developed PET, the mean GA at diagnosis was 37  week 
(range 31–41  week). In total, 7 (28.0%) women were 
diagnosed with severe PET and 6 (24.0%) developed 
multi-system disease. At baseline, the mean arterial blood 
Table 1 Summary of donor demographic analysis.
Control (n = 25) PET (n = 25)
Maternal age, years (range) 30.5 (24.0–38.0) 31 (22.0–36.0)
Body mass index, median (25th–75th IQR), unit 26.2 (22.9–29.2) 25.5 (22.9–29.7)
Ethnicity white Caucasian, frequency (%) 25 (100) 25 (100)
Mean arterial blood pressure, median (25th–75th IQR), unit 92.7 (89.3–96.7) 117.3**** (113.8–124.8)
Vitamin D supplementation (400 IU daily); pre-pregnancy total (%), 1st trimester 
total (%)
10 (40.0)
9 (36.0)
5 (20.0)
3 (12.0)
Season at recruitment (15 weeks): summer, total (%); winter, total (%) 10 (40.0)
15 (60.0)
11 (44.0)
14 (56.0)
Positive smoking status at 15 week, total (%) 2 (8.0) 4 (16.0%)
Gestation at PET diagnosis, mean (range) (week) – 37 (31–41)
Term PET (gestation ≥37 week), frequency (%) – 14 (56.0%)
Preterm PET (gestation <37 week), frequency (%) – 11 (44.0)
Severe preterm PET (gestation <34 week), frequency (%) – 1 (4.0)
Gestational age at delivery, mean (25th–75th IQR) (weeks) 41.0 (40.0–41.0) 39.0**** (37.0–40.0)
Fetal birthweight, median (25th–75th IQR) (g) 3650 (3275–4040) 3030** (2580–3535)
Fetal small for gestational age, frequency (%) 0 (0) 3 (12.0)
Stillbirth, frequency (%) 0 (0) 1 (4.0)
Comparison of baseline maternal–fetal clinical and disease demographics in normotensive pregnant women (n = 25) and those pregnant women who 
prospectively developed preeclampsia (PET; n = 25). Cases were matched for age, ethnicity and body mass index (BMI). Statistically significant variations 
are indicated, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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pressure (MABP) was significantly higher in the PET group 
comparatively (P < 0.0001). The mean GA at delivery was 
significantly earlier in those with PET (P < 0.0001), with 
the median fetal birthweight significantly lower than 
those in the uncomplicated cohort (P < 0.05). A healthy 
non-pregnant female group (n = 9) was also recruited 
for comparison.
Serum vitamin D metabolite analysis
In serum, five serum vitamin D metabolites were 
consistently quantifiable in both the pregnant 
(normotensive and PET women) and non-pregnant groups: 
25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 24,25(OH)2D3, 
3-epi-25(OH)D3, as summarised in Fig.  1 and Table  2. 
Considering maternal ‘vitamin D status’, the Institute 
of Medicine (IOM) definition of vitamin D ‘deficiency’ 
is 25(OH)D <20 ng/mL (50 nM/L) and ‘insufficiency’ as 
25(OH)D >20 ng/mL but <30 ng/mL (75 nM/L) (42). In the 
normotensive pregnancy group, 14 (56.0%) women were 
defined as vitamin D deficient and 8 (32.0%) insufficient. 
In the PET group, 18 (72.0%) were vitamin D deficient 
and 6 (24.0%) insufficient. Although median 25(OH)
D3 concentrations were lower in the PET group (median 
33.1, IQR 20.5–50.8 nmol/L) compared to the control 
pregnancy group (44.7, 19.1–63.5 nmol/L), this was not 
significant (P = 0.240). Conversely, in the non-pregnant 
group, all women were sufficient (46.8; 42.8–91.0 nmol/L), 
with 25(OH)D3 levels significantly higher than values for 
PET (P = 0.04).
Figure 1
Serum vitamin D metabolites in non-pregnant women and pregnant women at 15-week gestation. Serum concentrations of (A) 25-hydroxyvitamin D3 
(25(OH)D3) nmol/L; (B) 25-hydroxyvitamin D2 (25(OH)D2) nmol/L; (C) 3-epi-25(OH)D3 nmol/L; (D) 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) pmol/L; 
(E) 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) nmol/L. Sample groups were non-pregnant (black; n = 9), normotensive pregnancies (red; n = 25) and those 
who later developed pre-eclampsia (blue; n = 25). Median with interquartile range are shown. Statistically significant variations are indicated, *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
Table 2 Summary of serum vitamin D metabolites in pregnant women at 15-week gestation and non-pregnant controls.
Non-pregnant (n = 9) (median; IQR) Control (n = 25) (median; IQR) PET (n = 25) (median; IQR)
25(OH)D3 (nmol/L) 46.8 (42.8–91) 44.7 (19.1–63.5) 33.1 (20.5–50.8)
25(OH)D2 (nmol/L) 1.17 (0–1.6) 4.8 (4.2–8.3) 4.7 (0–10.0)
1,25(OH)2D3 (pmol/L) 85.6 (47.3–117.4) 336.3 (245.5–508.4) 388.8 (304.2–468.4)
C3-Epi-25(OH)D3 (nmol/L) 3.2 (1.7–4.4) 2.5 (1.3–3.7) 2.6 (1.7–3.1)
24,25(OH)2D3 (nmol/L) 9.7 (5.5–10.7) 6.5 (2.07–10.7) 3.2 (1.37–12.9)
Comparison of serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3) nmol/L, 25-hydroxyvitamin D2 (25(OH)D3) nmol/L, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) pmol/L, 3-epi-25(OH)D3 nmol/L, 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) nmol/L in non-pregnant (n = 9), healthy normotensive 
pregnancies (n = 25) and those who later developed pre-eclampsia (PET; n = 25), with median values with interquartile range interval shown.
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Consistent with previous studies (38), a significant 
seasonal difference in serum 25(OH)D3 was observed, 
with higher concentrations in summer (median 50.8; IQR 
39.3–59.7 nmol/L) than winter (21.3; 14.1–41.7 nmol/L) 
(P = 0.0004). Sub-group analysis revealed that in the 
PET group, women pregnant during winter (24.8; 
15.4–37.0 nmol/L) had significantly lower 25(OH)D3 levels 
than those pregnant in summer (50.7; 33.1–57.3 nmol/L) 
(P = 0.002). In the normotensive group, 25(OH)D3 levels 
were again lower in winter (20.8; 9.9–63.2 nmol/L) than 
summer (55.2; 42.0–64.6 nmol/L), almost reaching 
significance (P = 0.05).
Serum concentrations of 25(OH)D2 were similar 
in the normotensive (4.8; 4.2–8.3 nmol/L) and PET 
(4.7; 0–10.0 nmol/L) groups (P = 0.352), and were, as 
anticipated, much lower than circulating 25(OH)D3 levels. 
No significant correlation between serum 25(OH)D2 and 
25(OH)D3 in either the normotensive (r = −0.15, P = 0.48) 
or PET (r = 0.00, P > 0.10) groups was measured. 25(OH)D2 
levels were significantly lower in the non-pregnant group 
comparative to both the PET (P = 0.02) and normotensive 
women (P = 0.001). There was no significant difference 
in serum concentrations of 3-epi-25(OH)D3 between 
the normotensive pregnant (2.5; 1.3–3.7 nmol/L), 
Figure 2
Effect of maternal vitamin D status (serum 25-hydroyxvitamin D3) upon other serum vitamin D metabolites at 15-week gestation; comparative analysis in 
healthy pregnant controls and prospective PET cases. Serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3) were correlated with C3-epi-25(OH)D3 
(nmol/L), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)(pmol/L) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) (nmol/L) in healthy pregnant controls (A) and 
prospective pre-eclampsia (PET) cases (B). Statistically significant correlations are indicated as P values, with Pearson R values shown.
Figure 3
Relationship between excreted urinary vitamin D metabolites. Urine concentrations 25(OH)D3 were correlated with 24,25(OH)2D3 (nmol/L) in  
non-pregnant (A), healthy pregnant controls (B) and prospective pre-eclampsia (PET) cases (C). All nmol/L. Statistically significant correlations are 
indicated as P values, with Pearson R values shown.
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PET  (2.6; 1.7–3.1 nmol/L) and non-pregnant (3.2; 
1.7–4.4 nmol/L) cohorts. There was a significant positive 
correlation between 25(OH)D3 and 3-epi-25(OH)D3 in 
the normotensive pregnancy group (r = 0.645, P = 0.0005), 
but this was not evident in women who developed PET 
(r = 0.195, P = 0.349) (Fig. 2).
Distinct from previous publications from the 
SCOPE study (43), 1,25(OH)2D3 and 24,25(OH)D2D3 
concentrations were both quantifiable in serum samples. 
No significant difference in 1,25(OH)2D3 concentrations 
was measured in the PET (388.8; 304.2–468.4 pmol/L) 
comparative to normotensive pregnant group (336.3; 
245.5–508.4 pmol/L). Consistent with previous reports 
(21), 1,25(OH)2D3 levels were significantly higher in 
both the PET (P < 0.0001) and normotensive (P = 0.0005) 
women compared to the non-pregnant group (85.6; 
47.3–117.4 pmol/L).
No significant difference in serum 24,25(OH)2D3 was 
observed across the 3 groups. Similar to 1,25(OH)2D3, no 
difference in 24,25(OH)2D3 circulating concentrations in 
the PET (3.2; 1.4–12.9) and normotensive (6.5; 2.1–10.7) 
groups was measured. However, as summarised in Fig. 2, 
serum 25(OH)D3 levels significantly correlated with 
24,25(OH)2D3 (r = 0.43, P = 0.03) in the normotensive 
women, whilst in those who developed PET no similar 
correlation (r = 0.25, P = 0.23) was observed. The 
significant negative relationship between 24,25(OH)2D3 
and 1,25(OH)2D3 measured in the normotensive group 
(r = −0.48, P = 0.02) was lost in those who developed 
PET (r = −0.15, P = 0.484). No correlation between 
serum 25(OH)D3 and 1,25(OH)2D3 was observed for 
either group.
Urinary vitamin D analysis
Urinary 25(OH)D3 and 24,25(OH)2D3 were consistently 
quantifiable in both pregnant and non-pregnant groups. 
A significant positive correlation between urinary 
24,25(OH)2D3 and 25(OH)D3 concentrations was 
measured across the non-pregnant (r = 0.90, P = 0.002), 
normotensive (r = 0.64, P = 0.0006) and PET groups 
(r = 0.65, P = 0.0005) (Fig.  3). As summarised in Fig.  4, 
urinary 25(OH)D3 concentrations were significantly 
lower in the PET group (15.2; 12.0–22.2 ng/g creatinine) 
compared to normotensive pregnant women (22.9; 
15.3–72.1 ng/g creatinine) (P = 0.018). Concentrations of 
urinary 24,25(OH)2D3 were similarly significantly reduced 
in those women who developed PET (34.1; 16.6–62.8 ng/g 
creatinine) (P = 0.018) (Fig. 4 and Table 3). Measurement 
of the metabolites 1,25(OH)2D3 and 23,25(OH)2D3 was 
incorporated into the method, but these analytes could 
not be quantified as concentrations were below the lower 
limit of detection.
Discussion
Low maternal serum vitamin D concentrations in early 
pregnancy have been associated with an increased risk 
of PET (28), but the mechanisms underlying this remain 
unclear. Previously, we have demonstrated that in 
Figure 4
Urine vitamin D metabolite analysis in pregnant women at 15-week 
gestation. Urinary concentrations of (A) 25-hydroxyvitamin D3 (25(OH)
D3) nmol/L and (B) 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) nmol/L 
normalised for urinary creatinine (ng/g creatinine) for matched 
normotensive pregnancies (red) and those who later developed 
pre-eclampsia (PET; blue). Median with interquartile range values is 
shown. Statistically significant variations are indicated, *P < 0.05.
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pregnant women with PET, multiple vitamin D metabolic 
pathways are dysregulated comparative to healthy normal 
pregnancy in the 3rd trimester and that this is evident 
for both serum and placental tissue vitamin D metabolites 
(21). Whilst placental vitamin D analysis offers the 
novel opportunity to delineate metabolism directly at 
the maternal–fetal interface, the clinical applications of 
this are limited due to the inaccessibility of this tissue 
throughout normal pregnancy. Given the prominent 
alterations in circulating vitamin D physiology across 
pregnancy, additional methods to ascertain vitamin D 
metabolism across gestation may be informative.
To advance these observations, we performed a detailed 
comparative analysis of serum vitamin D metabolites in 
a cohort of nulliparous ‘low-risk’ pregnancies at 15-week 
gestation of which half prospectively developed PET. To 
further enhance this approach, a novel urinary vitamin D 
metabolite quantification method was incorporated. Given 
the anticipated low concentrations of steroid metabolites 
present in urine, the analytical method employed utilised 
a derivatization procedure using PTAD to enhance both 
the sensitivity and separation of individual metabolites.
Consistent with our own data set in the West Midlands 
(21), vitamin D deficiency was highly prevalent in the 
SCOPE cohort from Ireland, particularly in winter months, 
with 64% (n = 32) of pregnant women having 25(OH)D3 
levels <50 nmol/L at 15-week gestation. We anticipate that 
this would be higher still if the cohort included pregnant 
women with darker skin pigmentation as demonstrated in 
large epidemiological studies (44). Despite current clinical 
recommendations for pregnant women to take daily 
vitamin D supplementation (45, 46), in this cohort only 
20% of women reported taking preconception vitamin D 
supplementation and by the 1st trimester adherence to 
supplementation advice dropped to 18% of women.
In previous published work, the SCOPE whole 
dataset (n = 1768) which similarly utilised LC MS–MS 
to measure circulating 25(OH)D3, 3-epi-25(OH)D3 and 
25(OH)D2 concluded that in women with 25(OH)D3 
levels >75 nM a protective effect (adjusted OR: 0.64; 95% 
CI: 0.43, 0.96) upon PET plus SGA outcome is evident 
following adjustment for potential confounding factors, 
including sociodemographic status, season, ethnicity, 
smoking status, exercise frequency and BMI (43). In the 
smaller subset of the SCOPE cohort assessed here only 
3 (12.0%) of the pregnant cohort, none of which were 
in the PET group (maximum 25(OH)D3 = 60.9 nmol/L) 
had 25(OH)D3 levels >75 nmol/L. However, circulating 
25(OH)D3 concentrations in those who developed PET 
were only statistically lower than the non-pregnant 
group. This may simply reflect the smaller cohort size 
resulting in a type 1 error, but may also be due to the 
heterogeneity of the PET cohort with respect to both 
timing of disease onset and progression. Our findings 
are however consistent with Powe and coworkers (47), 
who similarly concluded there was no significant 
difference in 25(OH)D3 levels in pregnant women 
who subsequently developed PET compared to those 
who remained normotensive (27.4 ± 1.9 vs 28.8 ± 0.80; 
P = 0.435). In this particular study, DBP and free 
25(OH)D levels were also assessed, with no difference 
between the PET and normotensive group data (47). As 
25(OH)D3 reflects total body stores, the levels of this 
metabolite may be preserved during the early stages of 
PET. It appears that 25(OH)D3 alone is unlikely to be an 
informative vitamin D metabolite within the context of 
ascertaining potential risk of PET.
Although we did not observe any statistically 
significant differences in concentrations of serum 
vitamin D metabolites between the two pregnancy 
groups, the associations between these metabolites varied 
significantly. In women who developed PET, there was no 
positive correlation between serum 25(OH)D3 and the 
vitamin D catabolites 3-epi-25(OH)D3 and 24,25(OH)2D3. 
Albeit not clearly understood, alternative metabolism of 
vitamin D via epimerisation to 3-epi-25(OH)D3 results 
in the formation of 3-epi-1,25(OH)2D3, which binds to 
VDR to activate target gene transcription. Importantly, 
3-epi-1,25(OH)2D3 appears a less potent VDR agonist 
than 1,25(OH)2D3, which may have physiological 
consequences (48). In normal pregnancy, 3-epi-25(OH)2D3 
appears directly linked to 25(OH)D3 concentrations (43); 
however, in the SCOPE cohort this relationship was lost 
only in those women who developed PET.
Table 3 Urinary concentrations of 25(OH)D3 nmol/L and 24,25(OH)2D3 nmol/L.
Non-pregnant Control PET
25(OH)D3 55.8 (14.3–84.7) 22.9 (14.8–63.5) 14.8 (11.9–22.5)
24,25(OH)2D3 55.4 (22.4–118.8) 84.1 (13.5–395.9) 35.6 (15.5–63.7)
Urinary vitamin D metabolite concentrations were normalised for urinary creatinine (ng/g creatinine) in non-pregnant controls (n = 9), normotensive 
pregnancies (n = 25) and those who later developed pre-eclampsia (PET; n = 25). Mean values with interquartile range are shown.
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A trend towards elevated serum 1,25(OH)2D3 was 
also observed in the PET samples. This may reflect a 
compensatory response to lower 25(OH)D3, but may also 
contribute to depletion of 25(OH)D3. Healthy pregnancy 
is characterised by a drive towards 1,25(OH)2D3 
production (21), and there is also evidence of increased 
upregulation of CYP27B1 (1α-hydroxylase) and CYP24A1 
(24α-hydroxylase) in the placenta of women with PET 
(4). Increased metabolism of 25(OH)D3 to 1,25(OH)2D3 
may also be secondary to decreased total serum calcium 
concentrations, which arise during normal human 
pregnancy (49). Within the context of PET, serum 
calcium concentrations are usually significantly reduced 
(50). A  prospective study measuring the urine calcium/
creatinine (Ca:Cr) clearance ratio also found women with 
PET excrete significantly less calcium (n = 60) compared to 
normotensive controls (51). In the current study, this may 
account for enhanced renal 25(OH)D3 re-uptake, limiting 
metabolite excretion.
Intriguingly, serum levels of 25(OH)D2 were 
significantly higher in both pregnancy groups relative 
to non-pregnant controls. The explanation for this 
is unclear as vitamin D2 is principally obtained 
from plants and mushrooms. One possibility is that 
enhanced circulating 25(OH)D2 is due to dietary 
modifications undertaken by women when they are 
pregnant. Furthermore, when considering 25(OH)D3 
and 25(OH)D2 together, no significant difference in 
total vitamin D status was measured. Therefore, despite 
significantly lower 25(OH)D3 concentrations in those 
pregnant women who developed PET compared to 
the non-pregnant group, overall vitamin D status was 
not altered. This is consistent with previous data from 
the Osteoporotic Fractures in Men Study, which found 
higher 25(OH)D2 levels not to correlate with higher total 
25(OH)D, and that increased 25(OH)D2 concentrations 
were associated with lower 25(OH)D3 levels (P < 0.01) 
(52). Recent supplementation data similarly indicated 
that 25(OH)D2 supplementation decreased serum 
25(OH)D3 levels (53). In serum, 25(OH)D2 binds to 
the serum DBP carrier with lower affinity, and this has 
been postulated as an explanation for the increased 
serum clearance of 25(OH)D2 relative to 25(OH)D3 
(54). However, in the current study, it was noticeable 
that 25(OH)D2 was not quantifiable in urine samples, 
suggesting that renal handling of 25(OH)D2 bound to 
DBP is efficient enough to limit urinary excretion of 
25(OH)D2. Re-absorption of 25(OH)D2 from glomerular 
filtrates into proximal tubules may lead to increased 
synthesis of 24,25(OH)2D2 and 1,25(OH)2D2, but as 
neither of these metabolites was measured in the current 
study, this remains to be confirmed.
To our knowledge, this is the first report of vitamin 
D metabolite quantification in the urine of pregnant 
women. The method utilised was adapted from that 
reported by Ogawa and coworkers who quantified 
25(OH)D3 and 24,25(OH)2D3 in spot urine samples 
(1 mL) from healthy male subjects (n = 20) pre and post 
vitamin D supplementation (40). This method used the 
derivatization agent PTAD to quantify 25OHD3 and 
24,25(OH)2D3 in a 700 µL spot urine. This optimised 
method presents a reference range for urinary vitamin D 
during pregnancy, along with comparison to circulating 
serum levels. To our knowledge, this is the first time 
circulating and urinary vitamin D has been compared for 
clinical analysis, describing changes in both circulating 
and excreted levels of vitamin D on pregnancy outcome. 
This method combined with serum analysis will provide 
a comprehensive assessment in vitamin D metabolism in 
clinical conditions related to vitamin D deficiency. This 
method was capable of quantifying urinary 25OHD3 
and 24,25(OH)2D3; however, under the current method 
conditions, levels of 1α,25(OH)2D3 and 23,25(OH)2D3 
could not be measured following derivatization, as these 
concentration were below the limits of detection. To assess 
the ability to quantify these analytes in urine, method 
development will be required on a later generation mass 
spectrometer that will enable reduced detection limits.
In pregnancy, urinary 24,25(OH)2D3 concentrations 
were approximately 3-fold higher than 25(OH)D3, 
representing the predominant excreted vitamin D 
metabolite. This was not evident in the non-pregnant 
group, for which urinary 25(OH)D3 and 24,25(OH)2D3 
concentrations were comparable. Furthermore, in 
the healthy non-pregnant females, median urinary 
25(OH)D3 concentrations were at least 2-fold higher 
than both pregnant groups, in particular, those who 
developed PET. Together, these findings are consistent 
with an increased role for 25(OH)D3 in pregnancy, 
with significantly enhanced classical and non-classical 
placental 1,25(OH)2D3 production and turnover from the 
1st trimester (21, 22). Reduced 25(OH)D3 excretion may 
also reflect increased neonatal vitamin D metabolism, as 
25(OH)D3 readily diffuses across the placenta principally 
to permit later fetal bone development and growth (55). 
In rat models, VDR expression is demonstrated from a 
very early stage in fetal development (56).
Urinary 25(OH)D3 and 24,25(OH)2D3 were 
significantly correlated in both the normotensive and 
PET groups. This is consistent with serum 25(OH)D3 and 
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24,25(OH)2D3 in normal pregnancy, as evidenced here and 
our previous study (21). However, in normal pregnancy, 
serum concentrations of 25(OH)D3 and 24,25(OH)2D3 did 
not correlate with their respective urinary concentrations. 
Given the number of known extra-renal sites of vitamin D 
storage and metabolism, including the placenta, this may 
be anticipated. Furthermore, the kidney has the capacity 
to actively reabsorb vitamin D metabolites in a DBP-
megalin-dependent manner (57), and this may contribute 
to the lack of correlation between serum and urinary 
vitamin D metabolites.
In the current study, urinary vitamin D metabolite 
analysis suggests that dysregulation of vitamin D 
metabolism occurs at an early stage in women who go 
on to develop PET. Within the context of PET, both 
urinary 25(OH)D3 and 24,25(OH)2D3 concentrations 
were significantly decreased compared to those who 
were normotensive throughout pregnancy. As discussed, 
alongside this increased serum concentrations of 
1,25(OH)2D3 were measured in those with PET. This 
increased vitamin D metabolism to 1,25(OH)2D3 may arise 
secondary to decreased serum calcium concentrations. 
Within the context of PET, serum calcium concentrations 
are significantly reduced. A prospective study measuring 
the urine calcium/creatinine (Ca:Cr) clearance ratio also 
found women with PET excrete significantly less calcium 
(n = 60) compared to normotensive controls (51). This may 
account for enhanced renal 25(OH)D3 re-uptake, limiting 
metabolite excretion.
Urinary metabolite concentrations are susceptible to 
variation by factors including hydration status and overall 
renal function. Twenty-four-hour urine sample collections 
are considered the gold-standard measurement, but 
are cumbersome and reliant upon strict compliance. 
Spot samples and first morning void are widely deemed 
acceptable for analyte measures, provided the effect of 
sample dilution is quantified and appropriately adjusted 
(58, 59). At present, no consensus upon which is most 
appropriate adjustment technique; however, creatinine 
remains commonly applied. This simply calculates the 
ratio to creatinine concentrations and does not account 
for temporal variations in creatinine excretion rates (59). 
The potential value of a urinary marker of vitamin D status 
has wider clinical implications outside of pregnancy, and 
certainly, this method will be highly transferrable.
Moving forward, serial serum and urinary analyses 
at a set time-point would provide a more detailed insight 
into the pathogenesis of vitamin D dysregulation. It would 
have been interesting to include in this cohort more early-
onset PET cases (<34  week) (n = 1), which are typically 
more severe (60) and women of greater ethnic diversity 
(61). Subgroup analysis of those women who developed 
PET pre-term (≤37  week) (n = 9) did not reveal any 
significant differences with regards to the 5 major serum 
vitamin D metabolites measured (data not shown), but 
numbers were too small to draw any robust conclusions 
from this. The current study was based simply on the 
availability of sample material. In this setting, urinary 
25(OH)D3 measurements with n = 25 per sample group, 
and a difference of means of 13.86 ng/g creatinine resulted 
in statistical power of 0.588 at α = 0.05. To reach power 
of >0.8 would have required n = 41 per sample group. 
Nevertheless, our preliminary data indicate dysregulation 
of vitamin D metabolism may precede clinical onset of 
PET. This was evident from spot urinary analyses, which 
offer novel insights into the underlying pathogenesis of 
vitamin D dysregulation in PET. From the data presented, 
we demonstrate that routine measurement of serum 
25(OH)D3 alone provides only a limited perspective on the 
requirement for vitamin D in pregnancy. Detailed analysis 
of vitamin D metabolism, including renal catabolism and 
excretion is required.
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